Design Therapeutics, Inc. DSGN Return on equity

Return on equity at other companies

ALN

Alnylam PharmaceuticalsALNY

91.4%—

Intellia TherapeuticsNTLA

-56.3%-1.5pp

CRISPR TherapeuticsCRSP

-31.2%+43.7pp

Dyne Therapeutics, Inc.DYN

-58.9%-4.4pp

CytomX TherapeuticsCTMX

-37.8%—

Taysha Gene Therapies, Inc.TSHA

-97.3%-27.3pp

FAQ

What is Design Therapeutics, Inc.'s return on equity?

Design Therapeutics, Inc. (DSGN) reported return on equity of -31.3% in Q1 2026.

How has Design Therapeutics, Inc.'s return on equity changed year-over-year?

Design Therapeutics, Inc.'s return on equity decreased by 38.4% year-over-year, from -22.6% to -31.3%.

What is the long-term trend for Design Therapeutics, Inc.'s return on equity?

Over 3 years (2022 to 2025), Design Therapeutics, Inc.'s return on equity has grown at a 19.8% compound annual growth rate (CAGR), from -17.8% to -30.7%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.